Our blog: China’s technology, consumer and new retail insights

We’ve written a lot of articles on a variety of topics that can benefit everyone from a complete beginner to experienced marketers. Do a search for a specific topic of interest or read them in sequence for a broader view. It’s up to you.

LATEST CHINA MARKETING AND CONSUMERS INSIGHTS

Pharmaron headquarters building

Pharmaron: Drug R&D Infrastructure From Discovery to Clinic

Pharmaron is a China-based provider of drug research, development, and manufacturing services. It combines a contract research organization (CRO) with a contract development and manufacturing organization (CDMO), supporting pharmaceutical and biotechnology clients through discovery, preclinical testing, and clinical development. Its service portfolio covers small molecules, biologics, and cell and gene therapies. Its importance lies in […]

October 18, 2026
CNSA lunar spacecraft orbiting the Moon

CNSA: China’s Space Agency, Policy and Exploration Strategy

CNSA, the China National Space Administration, is China’s national space agency responsible for areas including civil space policy, exploration programs, and international cooperation. Its work connects scientific missions with industrial development, including dedicated oversight of commercial space.  China’s space progress offers a useful view of how the country develops complex technologies and organizes research partnerships. […]

October 17, 2026
WuXi AppTec Chengdu facility exterior

WuXi AppTec: China’s Integrated Drug R&D Services Engine

WuXi AppTec is headquartered in China and provides drug discovery, preclinical research, process development, and manufacturing services. Its contract research, development, and manufacturing organization (CRDMO) model supports pharmaceutical companies as they turn experimental molecules into medicines. The business matters because promising science needs reproducible production, reliable testing, and usable regulatory documentation. Its capabilities offer a […]

October 16, 2026
Legend Biotech building

Legend Biotech: CAR-T, CARVYKTI and Cell Therapy Scale

Legend Biotech has grown from a Nanjing startup into what the company describes as the world’s largest standalone cell therapy company, with more than 10,000 patients treated with CARVYKTI as of December 2025. The company reported $1.9 billion in CARVYKTI net trade sales for full-year 2025 and achieved franchise profitability, a milestone that few biotech […]

October 15, 2026
Insilico Medicine office

Insilico Medicine: Generative AI From Target to Clinic

Insilico Medicine is a global biotechnology company that uses generative AI to identify disease targets, design molecules, and advance drug candidates into human trials. Its lead candidate, rentosertib, reached Phase III patient dosing in September 2026.  The company offers a concrete case study of AI moving into pharmaceutical development, with China playing an important role […]

October 14, 2026
GenScript biotechnology company logo

GenScript: From Gene Synthesis to Biologics Infrastructure

GenScript is a biotechnology group that supplies gene synthesis, protein and antibody research services, and drug development and manufacturing support through ProBio. Its portfolio also includes industrial enzymes through Bestzyme. It sells the picks and shovels of biotech: genes to order, proteins on demand, and factory capacity to make them at scale. The company offers […]

October 13, 2026
Automated medical equipment production at Mindray

Mindray: How China Built a High-End Medtech Challenger

Mindray is a Chinese medical technology company headquartered in Shenzhen, and its recent progress shows why China’s high-end medtech sector deserves closer study. The company now competes across patient monitoring, ultrasound, diagnostics, anesthesia, critical care, surgery, and connected hospital technology.  In the first half of 2026, international business generated 53% of company revenue and grew […]

October 12, 2026
BeiGene biotechnology facility in China with company signage

BeiGene Is Now BeOne Medicines: From Chinese Roots to Global Oncology Scale

Is BeiGene a Chinese company?  The precise answer is: it is China-founded, but today’s corporate structure is global. BeiGene is no longer just a Chinese biotech story. In May 2025, the company completed a redomiciliation to Switzerland and rebranded as BeOne Medicines Ltd., a global oncology company with $5.3 billion in full-year 2025 revenue, a […]

October 11, 2026
LandSpace reusable booster landing test

LandSpace: Methane Rockets, Zhuque-3 and Reusable Launch

LandSpace became the first company worldwide to reach orbit with a methane-fueled rocket in July 2023. By 2025, this Beijing-based launch provider has moved from that historic Zhuque-2 achievement to testing Zhuque-3, a stainless-steel reusable vehicle designed to compete directly with SpaceX’s Falcon 9.  That establishes a concrete recovery milestone. The next commercial test is […]

October 10, 2026
SpaceSail satellites orbiting Earth

SpaceSail (Qianfan): How China Is Building Its LEO Network

SpaceSail is the Chinese company building and operating Qianfan, also known as Thousand Sails, a low Earth orbit satellite network designed to provide broadband connectivity. Shanghai Spacesail Technologies, formerly Shanghai Spacecom Satellite Technology, operates it.  China’s Ministry of Industry and Information Technology confirmed 238 satellites launched by July 5, 2026. That figure measures deployment, rather […]

October 9, 2026
retail customer experience

How China Innovation Tours Redefine Retail Customer Experience for Global Brands

There is a moment that happens to almost every executive who visits China for the first time. They walk into a store. Not a concept store. Not a flagship. A functioning grocery outlet. A mid-market lifestyle shop. A fast-fashion chain in a tier-two city.  And they go quiet. Not because it is impressive. Because it […]

October 8, 2026
NMPA regulatory review concept

NMPA China: Drug and Medical Device Approval Explained

NMPA China refers to the National Medical Products Administration, China’s national regulatory body for medical devices and the authority responsible for drug registration. For any company seeking market access in China’s healthcare sector, NMPA China approval is the single most important regulatory milestone.  In 2025, the agency approved 14,187 medical devices and IVDs, an 8.0% […]

October 7, 2026